Publications

Q & A with Principal Investigator

Novartis invites scrutiny of effort to improve access to medicine


Effect of Novartis Access on Availability and Price of Medicines in Kenya

Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial 

Lancet Global Health Commentary on Article

Lancet Global Health Editorial on Article

Boston University Press Release on Article 


Prevalence and Treatment of Chronic Diseases in Kenya

East African Medical Journal


Perceptions on Access to Medicines for NCDs

PLoS One


Equity in Access to Non-Communicable Disease Medicines


Access to Asthma Medicines

Access to Asthma Medicines at the Household Level in Eight Counties of Kenya

International Journal of Tuberculosis and Lung Disease


Access to Diabetes Medicines

Access to Diabetes Medicines at the Household Level in Eight Counties of Kenya

Journal of Diabetology


Access to Asthma, Diabetes and Hypertension Medicines

Access to Medicines for Asthma, Diabetes and Hypertension in Eight Counties of Kenya

Tropical Medicine and International Health


Access to Antihypertensive Medicines

Access to Antihypertensive Medicines at the Household Level in Eight Counties of Kenya

Global Heart


Strategies for Improving Access and the Quality of Evidence

We reviewed the initiatives of twenty-one research-based global biopharmaceutical companies to assess their strategies for improving access and the quality of evidence on the impact of their initiatives.

Industry-Led Access-To-Medicines Initiatives in Low- and Middle- Income Countries: Strategies and Evidence

Health Affairs


Protocol

BMJ Open: Study protocol for a cluster-randomised controlled trial of an NCD access to medicines initiative: evaluation of Novartis Access in Kenya (Full Protocol)

ClinicalTrials.gov: Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative (Protocol Summary)


Presentations

Dr. Richard Laing’s presentation on the Evaluation of Novartis Access at the World Health Assembly in Geneva, Switzerland, on May 25th, 2016 (Full)

Dr. Richard Laing’s presentation on the Evaluation of Novartis Access at the Ecumenical Pharmaceutical Network forum in Tübingen, Germany, on May 19th, 2016 (Abbreviated)